Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BD Diagnostics, a segment of BD (Becton, Dickinson and Company), has submitted for US Food and Drug Administration (FDA) approval for its first fully automated molecular tests to identify and differentiate Herpes Simplex Viruses (HSV) types 1 and 2.
Subscribe to our email newsletter
The BD ProbeTec HSV-1 and HSV-2 Qx Amplified DNA assays will run on the BD Viper System with XTR Technology, which uses Strand Displacement Amplification technology to qualitatively detect and differentiate HSV-1 and HSV-2 DNA in clinician-collected external anogenital lesion specimens.
The new BD ProbeTec HSV-1 and HSV-2 Qx assays will improve accuracy and time to results over culture methods, which often take 2-10 days for results.
BD’s new automated HSV assays will provide laboratories with the capability to read up to 96 positive or negative results in about two and a half hours.
Using the BD Viper System with XTR Technology, laboratories also will be able to run tests for chlamydia and gonorrhea, along with HSV-1 and HSV-2, on a single automated run.
BD Diagnostics Women’s Health and Cancer vice president and general manager Wayne Brinster said that when caring for a patient who may be suffering from HSV, clinicians need a precise picture of what they are dealing with.
"Determining whether a patient has HSV and whether it is type 1 or 2 makes a big difference in how the infection is treated, especially with the increase in new anti-viral and suppressive therapies," Brinster said.